Quantifying antibody-mediated neutralization of SARS-CoV-2 directly in serum
New Scientific Publication
The emergence of mutant variants of SARS-CoV-2 and associated concerns about the effects of these mutations on the efficacy of vaccines and therapeutics has underscored the vital importance of understanding the antibody response to SARS-CoV-2.
In our recent paper “In vitro measurements of protein–protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum” we showcase the unique capabilities of our Fluidity One-W Serum platform and describe:
- A new type of in-solution receptor-binding competition assay that quantifies the affinity, concentration, and neutralization potential of antibodies against the SARS-CoV-2 spike protein.
- The ability of this platform to accurately and quantitatively profile the underlying protein interactions directly in serum.